Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive hone disease

Fitton, Andrew; McTavish, Donna

doi:10.1016/0378-5122(91)90266-s

Cited by 47 publications

(86 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This reflects itself in the binding of bisphosphonates to bone in vivo. Thus, at least 50% of most of the hydroxylbisphosphonates distribute themselves to bone (259), whereas in the case of clodronate (260,261) it is only about 20 -40%. Their preferred location in the skeleton is bone with a high turnover, namely trabecular bone.…”

Section: Pharmacokineticsmentioning

confidence: 99%

Bisphosphonates: Mechanisms of Action

1998

View full text Add to dashboard Cite

Section: Pharmacokineticsmentioning

confidence: 99%

Bisphosphonates: Mechanisms of Action

1998

View full text Add to dashboard Cite

“…PAMIDRONATE (disodium 3-amino-1-hydroxypropylidene-1,1-bisphosphonate pentahydrate), a second generation bisphosphonate, has been used in the treatment of patients with tumor-associated hypercalcemia, and reduction in serum calcium in response to this drug has been reported [1][2][3]. It has generally been accepted that pamidronate reduces serum calcium through the suppression of osteoclast activity.…”

mentioning

confidence: 99%

Pamidronate Treatment in Patients with Tumor-Associated Hypercalcemia: Pharmacological Effects and Pharmacokinetics.

Oiso

Tomita

Hasegawa³

et al. 1994

Endocr J

View full text Add to dashboard Cite

Abstract. The purpose of this study was to investigate the effects of pamidronate, a second generation bisphosphonate, on the change in calcium homeostasis in patients with tumor-associated hypercalcemia. Eight patients with tumor-associated hypercalcemia received intravenous infusion of pamidronate (45 mg) and their high mean serum calcium concentration significantly decreased from 3.56 mmol /L_, to 2.62 mmol/L 7 days after treatment. Serum intact PTH before treatment had been suppressed to below normal in all patients but returned to normal range in six patients within 7 days after treatment. Urinary PTH related peptide (PTHrP) excretion before treatment had been elevated in seven patients and then significantly increased further after pamidronate therapy. The serum bone Gla protein concentration was not apparently changed by the treatment. Pamidronate in serum was rapidly eliminated after the treatment and urinary excretion reached a plateau on the second day (13.8% of the administered dose), suggesting that the major portion of the infused dose had been distributed to the bone and other tissues. These findings suggest that pamidronate has a potent hypocalcemic effect and that PTHrP production in malignant tumors could be affected by pamidronate therapy.

show abstract

“…5). Hanhijarvi et al 1989;Fitton & McTavish 1991). The accumulation capacity for clodronate was somewhat lower than that for the two other drugs.…”

Section: Resultsmentioning

confidence: 99%

Accumulation of Bisphosphonates in Human Artery and their Effects on Human and Rat Arterial Function in vitro

Ylitalo

Kalliovalkama

et al. 1998

Pharmacology & Toxicology

View full text Add to dashboard Cite

Ah.wocf: Clodronate. etidronate and pamidronate are bisphosphonates introduced in the treatment of hypercalcaemia and osteoporosis. Interestingly, they also inhibit development of experimental atherosclerosis and affect smooth muscle tone of isolated rat tail artery. We have studied in vitro whether these hydrophilic compounds 1) accumulate in the wall of the human artery, 2) influence human arterial tone, and 3) interfere with the vascular action of L-type Ca2+ antagonists. Human internal mammary artery rings were incubated with ''C-labelled bisphosphonates. After a 2-hr incubation, the ratios of artery-to-incubate concentrations with 4 and 40 pmolil of clodronate were, respectively, 3.020.5 (mean?S.E.M.) and 1.320.2, with 4 and 40 pmol/l of etidronate 7.4+-0.9 and 3.2?0.4, and with 0.4 and 4 pmol/l of pamidronate 4.7+0.7 and 3.920.8. Both tested bisphosphonates, clodronate and pamidronate, reduced the arterial contractile force induced by a-adrenergic stimulation with noradrenaline and membrane depolarization with high concentration of KCI. Clodronate also decreased the arterial contraction induced by cumulative addition of Ca2+ with KCI as the agonist, and had an additive inhibitory effect on this response with the L-type Ca2+-channel blocker nifedipine. The results demostrate that I ) bisphosphonates accumulate markedly in human artery, 2) clodronate and pamidronate reduce human arterial contactile force to a-adrenergic and depolarizing stimuli, and 3) as shown with clodronate, bisphosphonates may exert an additive inhibitory effect on human arterial contractions with an L-type Ca2+-channel blocker.

show abstract

Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive hone disease

Cited by 47 publications

References 0 publications

Bisphosphonates: Mechanisms of Action

Bisphosphonates: Mechanisms of Action

Pamidronate Treatment in Patients with Tumor-Associated Hypercalcemia: Pharmacological Effects and Pharmacokinetics.

Accumulation of Bisphosphonates in Human Artery and their Effects on Human and Rat Arterial Function in vitro

Contact Info

Product

Resources

About